Precision BioSciences has joined the club of publicly traded gene editing biotech companies, raising $126 million in its stock market debut.
On Wednesday evening, Durham, NC-based Precision Bio sold 7.9 million shares for $16 apiece, which was right in the middle of its targeted price range. Those shares are expected to begin trading on the Nasdaq exchange Thursday under the stock symbol “DTIL,” which the company says stands for “dedicated to improving life.”
Much of the attention in gene editing has focused on CRISPR technology. CRISPR uses an enzyme to make cuts in the genome, which in turn allows the DNA… Read more »
UNDERWRITERS AND PARTNERS